Connect Biopharma Holdings Limited is a biotechnology business based in the US. Connect Biopharma Holdings Limited shares (CNTB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.86 – an increase of 6.67% over the previous week. Connect Biopharma Holdings Limited employs 81 staff and has a trailing 12-month revenue of around $24.1 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.86 |
|---|---|
| 52-week range | $0.77 - $2.66 |
| 50-day moving average | $0.97 |
| 200-day moving average | $1.18 |
| Wall St. target price | $7.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.39 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.8561 from 2025-03-14
| 1 week (2025-03-07) | 0.72% |
|---|---|
| 1 month (2025-02-14) | -7.19% |
| 3 months (2024-12-17) | -19.24% |
| 6 months (2024-09-17) | -33.12% |
| 1 year (2024-03-15) | -34.15% |
|---|---|
| 2 years (2023-03-16) | -24.90% |
| 3 years (2022-03-16) | 2.8 |
| 5 years (2020-03-13) | N/A |
| Revenue TTM | $24.1 million |
|---|---|
| Operating margin TTM | 24.64% |
| Gross profit TTM | $24.1 million |
| Return on assets TTM | -12.13% |
| Return on equity TTM | -17.92% |
| Profit margin | -88.66% |
| Book value | $2.00 |
| Market Capitalization | $47.3 million |
TTM: trailing 12 months
We're not expecting Connect Biopharma Holdings Limited to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Connect Biopharma Holdings Limited's shares have ranged in value from as little as $0.7654 up to $2.66. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Connect Biopharma Holdings Limited's is -0.475. This would suggest that Connect Biopharma Holdings Limited's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Connect Biopharma Holdings Limited has bucked the trend.
To put Connect Biopharma Holdings Limited's beta into context you can compare it against those of similar companies.
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California. .
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Check out the best-performing ETFs so far in 2025.